Pfizer bets on weight-loss drugs to power its next decade
Drugmaker releases new data on experimental weight-loss shot and outlines strategy to claw its way to leadership position in competitive market
๐จ๐ฆ ์บ๋๋ค ยท "COMPETITIVE" ยท ์ด 2๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
50.0
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 677๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 50.0(๊ท ํ)์ ๋๋ค. ๊ธ์ 1๊ฑด(0.1%)ยท์ค๋ฆฝ 676๊ฑด(99.9%)ยท๋ถ์ 0๊ฑด(0.0%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 0.0(์ค๋ ๊ท ํ)์ ๋๋ค.
Drugmaker releases new data on experimental weight-loss shot and outlines strategy to claw its way to leadership position in competitive market
MONTREAL โ Cogeco Communications Inc. and Cogeco Inc. say they expect to take a non-cash impairment charge of about $1.7 billion related to its U.S. telecommunications segment. The companies say the charge, net of deferred income taxes, reflects the competitive environment in which they operate in the United States. The exact amount will be finalized [โฆ]